On January 3, Gelonghui reported that Chongqing Taiji Industry (600129.SH) announced that on January 2, 2025, its wholly-owned subsidiary, Taiji Group Macau Pharmaceutical Research Institute Co., Ltd. (referred to as the Macau Company), received the "Chinese Patent Medicine Registration Certificate" from the Macau Drug Regulatory Authority for Huagai Granules [Taiji] (Specification: 4.13g per bag).
The formula for this product is derived from the Song Dynasty's "Taiping Huimin Heji Fang" and is included in the "Classical Famous Prescription Catalogue (First Batch)" issued by the National Administration of Traditional Chinese Medicine, intended for use in respiratory system medications. Its therapeutic function includes: dispersing the lungs and relieving the exterior, eliminating phlegm and stopping cough. It is used for symptoms such as lung cold evil, cough with shortness of breath, chest fullness, stiff neck and back, dizziness and lightheadedness, and unproductive phlegm with wheezing sounds. Huagai Granules [Taiji] is a non-prescription Chinese Patent Medicine category in Macau. So far, the company has invested a total of 4.32 million yuan (unaudited) in research and development costs for this product.
